Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 6/20 | 0.54 |
| ▸ | CDK7 | P50613 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 4/20 | 0.53 |
| ▸ | ULK1 | O75385 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31251253 | 0.91 | IGF1R (0.66) | PTK2CDK7CDK9IGF1RULK1 | |
| SCHEMBL32690424 | 0.83 | ULK1 (0.58) | PTK2CDK7CDK9IGF1RULK1 | |
| SCHEMBL19867256 | 0.83 | ALK (0.52) | PTK2CDK7IGF1RALKMET | |
| SCHEMBL25002639 | 0.82 | ALK (0.55) | PTK2CDK7CDK9IGF1RULK1 | |
| SCHEMBL32690420 | 0.81 | PTK2 (0.76) | PTK2CDK9IGF1RALKMET | |
| SCHEMBL31251107 | 0.80 | CDK7 (0.58) | PTK2CDK7CDK9IGF1RULK1 | |
| SCHEMBL31251194 | 0.79 | CDK7 (0.53) | PTK2CDK7CDK9ALKMET | |
| SCHEMBL26906721 | 0.79 | CDK9 (0.59) | PTK2CDK7CDK9IGF1RULK1 | |
| SCHEMBL29904658 | 0.79 | CDK9 (0.59) | PTK2CDK7CDK9IGF1RULK1 | |
| SCHEMBL31251139 | 0.78 | CDK7 (0.53) | PTK2CDK7CDK9ALKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | UNOGEN BIOTECH LTD (US) | 2026-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | ALK, ERBB2, ERBB3 | PTK2 84/4885CDK7 159/4885CDK9 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.